Page 59 - BPOM Terbitkan EUA Vaksin Comirnaty untuk Perluasan Penggunaan Booster Anak Usia 16 – 18 Tahun

Judul : BPOM Publishes EUA Comirnaty Vaccine for the 16 to 18 Years
Nama Media : viva.co.id
Tanggal : 8/2/2022
Halaman/URL : https://www.viva.co.id/english/1504826-bpom-publishes-eua-
comirnaty-vaccine-for-the-16-to-18-years
Tipe Media : Media Online

The Food and Drug Supervisory
Agency (BPOM) has approved the
addition of posology booster doses
for adolescents, especially for ages
16 to 18 years. This approval has the
purpose of expanding the Emergency
Use Authorization (EUA) for the
Comirnaty Vaccine.

"The Comirnaty vaccine is a
COVID-19 vaccine with an mRNA
platform developed by Pfizer-
Biontech. The Comirnaty vaccine is
one of 13 COVID-19 vaccines that
have received EUA approval in
Indonesia," Head of BPOM, Penny
K. Lukito said in a statement.

Penny also revealed the approved booster dose of Comirnaty Vaccine is 1 dose (30 mcg/0.3
mL) for at least 6 months after the second dose of primary vaccination using Comirnaty
Vaccine (homologous booster).

The Comirnaty vaccine previously received EUA in Indonesia on July 14, 2021 with
indications for primary vaccination at the age of 12 years or older.

After that, BPOM again issued approval for the expansion of the Comirnaty Vaccine EUA for
the addition of posology booster doses for adults aged 18 years or over on January 2, 2022
(homologous booster) and January 11, 2022 (heterologous booster).